Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia × eryaspase × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Triple Negative Breast Neoplasms 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1

Interventions

Cyclophosphamide 304 Cytarabine 246 fludarabine phosphate 168 Methotrexate 153 Filgrastim 137 Etoposide 122 Busulfan 121 Rituximab 107 fludarabine 105 Peripheral Blood Stem Cell Transplantation 105 Radiotherapy 97 Vincristine 89 Cyclosporine 83 Daunorubicin 81 Antilymphocyte Serum 80 Dexamethasone 78 Mycophenolic Acid 71 Melphalan 71 Whole-Body Irradiation 68 Tacrolimus 67 Imatinib Mesylate 61 Idarubicin 59 Mercaptopurine 57 Azacitidine 56 Methylprednisolone 51 Granulocyte Colony-Stimulating Factor 51 Doxorubicin 51 Prednisone 48 Clofarabine 45 Mitoxantrone 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed

123 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡